SBIR Phase II: Gene Signature Screening for Pancreatic Cancer Therapeutics from Sonoran Desert Extracts

SBIR 第二阶段：从索诺兰沙漠提取物中筛选胰腺癌治疗药物的基因特征

• 批准号: 1127476
• 负责人: Richard Kris
• 金额: $ 36.46万
• 依托单位: Nuvogen Research
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-15 至 2014-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1127476&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Gene; Signature

This Small Business Innovation Research (SBIR) Phase II project is to address the high lethality of pancreatic cancer. Screening has begun with Phase IB funding, of natural products from the Sonoran Desert that have produced other promising drug candidates, testing effects on human pancreatic cancer cells. The objective of Phase II is to develop a drug candidate that alters expression of selected pancreatic cancer-related genes and that kills pancreatic cancer cells that express those genes. The drug candidates will be developed using a personalized medicine approach. The gene expression profiles (or genomics patterns) for many different pancreatic cancer tumors will be matched to the effects on genomics produced by the drug. This personalized approach could translate directly to clinical trials to pre-select patients most likely to respond to the drug. The broader impacts of this research are first to reduce deaths due to pancreatic cancer, which ranked fourth among the leading causes of cancer death with 35,240 deaths in the US in 2009. The 5-year survival rate for patients with metastatic disease is 1.8%. The societal impact and commercial value of targeting such a lethal disease are very high. Further, the personalized medicine approach to drug development will impact many oncology projects. The idea of matching each patient's genomics patterns with each drug that targets that pattern will be critical. Each kind of cancer is not one disease, but a wide spectrum of accumulated genomics changes that have to be addressed individually.

这项小型企业创新研究（SBIR）II期项目是为了解决胰腺癌的高致死性。筛查始于IB期资金，来自Sonoran沙漠的天然产品，这些产品还产生了其他有前途的候选药物，测试对人胰腺癌细胞的影响。 II期的目的是开发一种候选药物，该药物会改变选定的胰腺癌相关基因的表达，并杀死表达这些基因的胰腺癌细胞。候选药物将使用个性化医学方法开发。许多不同胰腺癌肿瘤的基因表达谱（或基因组学模式）将与对药物产生的基因组学的影响相匹配。这种个性化方法可以直接转化为临床试验，以预先选择该药物反应的患者。这项研究的广泛影响首先是减少由于胰腺癌而导致的死亡，这在2009年美国在美国的癌症死亡原因中排名第四。转移性疾病患者的5年生存率为1.8％。靶向这种致命疾病的社会影响和商业价值很高。此外，个性化药物开发的医学方法将影响许多肿瘤学项目。将每个患者的基因组学模式与靶向该模式的每种药物匹配的想法至关重要。每种癌症都不是一种疾病，而是必须单独解决的各种累积基因组学变化。